Related Experiment Videos
Haemoperfusion Combined With Xuebijing Injection Improves Inflammatory Status And Prognosis In Patients With
Fangqian Liang1, Yuyang Yang2, Meiqi Wang1
1Department of General Practice, North China University of Science and Technology Affiliated Hospital.
Journal of Visualized Experiments : Jove
|June 22, 2026
Summary
Combined therapy of haemoperfusion and Xuebijing injection significantly improved outcomes for end-stage renal disease (ESRD) patients. This approach reduced inflammation and improved renal function, immune status, and survival rates compared to haemoperfusion alone.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- End-stage renal disease (ESRD) presents significant challenges to patient quality of life and current clinical treatments.
- Microinflammation is a critical factor influencing prognosis in ESRD patients.
Purpose of the Study:
- To evaluate the efficacy and safety of combined haemoperfusion and Xuebijing injection in ESRD patients.
- To analyze the correlation between microinflammatory status and prognosis in ESRD.
Main Methods:
- Retrospective study of 100 ESRD patients divided into haemoperfusion with Xuebijing (HI) and haemoperfusion only (HT) groups.
- Assessment of inflammatory, immune, and renal function indexes, clinical efficacy, quality of life (SF-36), complication, and adverse reaction rates.
- Logistic regression and ROC analyses were used to identify prognostic factors and predict complication risk.
Main Results:
- The HI group showed significant improvements compared to pre-treatment values and the HT group (P < 0.05).
- HI group demonstrated lower inflammatory markers, improved renal function, reduced complications and adverse events.
- HI group exhibited higher immune markers, clinical efficacy, quality of life scores, and survival rates.
Conclusions:
- Combined haemoperfusion and Xuebijing therapy is effective in improving renal function, modulating inflammation and immune response in ESRD patients.
- This combined therapy offers favorable prognostic outcomes and warrants further clinical investigation.
- Inflammatory, immune, and renal function indexes are significant prognostic factors in ESRD patients.
Related Concept Videos
01:30Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
01:25Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...